Lessons from Epidemiology: The Burden of Liver Disease

Liver cirrhosis is responsible for more than 1 million deaths annually and the majority of these deaths are preventable. There is marked geographical variation in rates of mortality due to cirrhosis, and this variation in liver disease burden exemplifies the links between population risks for liver disease and mortality. The differing geographical distribution of the major risks factors for the development of liver disease including alcohol consumption, hepatitis C virus (HCV) infection, hepatitis B virus infection, and obesity and the metabolic syndrome has the potential to highlight opportunities for intervention, while the evolution of these risk factors provides insights into understanding the future burden of liver disease. This review focuses on the use of population data to identify high-risk areas and populations that would benefit from preventative interventions to reduce the mortality from liver disease. Specific strategies that are effective at the policy and public health levels are discussed to illustrate the impact these can have if widely implemented. The impact of therapies that have the potential to change the natural history of liver disease, including direct acting antivirals for HCV infection is also described. Finally, the challenges of describing the epidemiology of non-alcoholic fatty liver disease are highlighted to illustrate the need to understand the natural history of disease to inform and influence the development of novel therapies.

[1]  T. Therneau,et al.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.

[2]  D. Couper,et al.  Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. , 2016, Journal of hepatology.

[3]  H. Sørensen,et al.  Risk for Hepatocellular Carcinoma in Patients With Alcoholic Cirrhosis , 2012, Annals of Internal Medicine.

[4]  Alan Brennan,et al.  Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study , 2014, The Lancet.

[5]  J. Sung,et al.  A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. , 1987, JAMA.

[6]  A. Schoepfer,et al.  Therapy: Positioning of dilation in eosinophilic oesophagitis , 2016, Nature Reviews Gastroenterology &Hepatology.

[7]  R. Peto,et al.  Alcohol and mortality in Russia: prospective observational study of 151 000 adults , 2014, The Lancet.

[8]  J. Ioannidis,et al.  Is widespread screening for hepatitis C justified? , 2015, BMJ : British Medical Journal.

[9]  Alan Brennan,et al.  Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study , 2014, BMJ : British Medical Journal.

[10]  D. Randall,et al.  The increasing mortality burden of liver disease among opioid-dependent people: cohort study. , 2011, Addiction.

[11]  A. Treno,et al.  The relationship between minimum alcohol prices, outlet densities and alcohol-attributable deaths in British Columbia, 2002-09. , 2013, Addiction.

[12]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[13]  Chien-Jen Chen,et al.  Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. , 2016, Gastroenterology.

[14]  B. Neuschwander‐Tetri,et al.  End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.

[15]  E. Bjornsson,et al.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[16]  E. Bjornsson,et al.  Alcohol consumption and liver cirrhosis mortality after lifting ban on beer sales in country with state alcohol monopoly. , 2015, European journal of public health.

[17]  A. Nemtsov Alcohol-related human losses in Russia in the 1980s and 1990s. , 2002, Addiction.

[18]  D. Nickle,et al.  Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.

[19]  P. Maisonneuve,et al.  Sustained virological response to treatment in patients with chronic hepatitis C. , 2013, Journal of the American Medical Association (JAMA).

[20]  K. Kielland,et al.  All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. , 2013, Journal of hepatology.

[21]  Nobhojit Roy,et al.  Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition , 2015, The Lancet.

[22]  P. Gruenewald,et al.  Alcohol outlet densities and alcohol price: the British Columbia experiment in the partial privatization of alcohol sales off-premise. , 2013, Alcoholism, clinical and experimental research.

[23]  N. Sheron Alcohol and liver disease in Europe--Simple measures have the potential to prevent tens of thousands of premature deaths. , 2016, Journal of hepatology.

[24]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[25]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[26]  P. Vickerman,et al.  Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.

[27]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[28]  H. Janssen,et al.  Sustained virological response to treatment in patients with chronic hepatitis C--reply. , 2013, JAMA.

[29]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[30]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[31]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[32]  A. Sanyal Reply: To PMID 24818764. , 2015, Gastroenterology.

[33]  A. V. D. Meer,et al.  Faculty Opinions recommendation of Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. , 2016 .

[34]  J. Hoofnagle,et al.  From non-A, non-B hepatitis to hepatitis C virus cure. , 2015, Journal of hepatology.